On January 15, 2021, Voyageur Pharmaceuticals Ltd. (TSXV:VM) closed the transaction. The company has amended the terms of the transaction. The company has now issued 10,340,000 flow-through units and 5,880,000 common units for gross proceeds of CAD 811,000. The company has issued 4,300,000 common units for gross proceeds of CAD 215,000 in its final tranche. The tranche involved participation from a Director of the company for 80,000 common units. The transaction included participation from 38 placees, including professional group participation of Charles Littlejohn, Independent Director, for 80,000 units, Ronald Les Sifton, Director for 570,000 units. The securities issued are subject to a four month hold period from the date of issuance. The company has received acceptance for filing documentation from TSX Venture Exchange with respect to this transaction.